Drugs / BIIB019
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01929746 | Oct 2013 → Mar 2014 | — | Biogen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00870740 | Feb 2009 → May 2012 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01797965 | Feb 2013 → Sep 2018 | relapsing-remitting multiple sclerosis | Biogen | Terminated | No outcome recorded |
| Phase 3 | NCT01462318 | Nov 2011 → Jan 2016 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT01064401 | May 2010 → Mar 2014 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-03-02 | AbbVie | Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis abbvie.com ↗ |
| 2016-05-27 | AbbVie | Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple Sclerosis abbvie.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01929746 ↗ |
| Known as | Daclizumab | “BIIB019 (Daclizumab)” NCT01797965 ↗1“BIIB019 (Daclizumab)” NCT01462318 ↗ |
| Route | Subcutaneous | “150 mg subcutaneous (SC) injection” NCT00870740 ↗ |